Objective: To evaluate efficacy and safety of lanreotide autogel (ATG) 120 mg injections every 4-8 weeks in somatostatin analogue-naïve patients with acromegaly. Design: Open, non-comparative, phase III, multicenter clinical study. Methods: Fifty-one patients (28 women, aged 19-78 yr): 39 newly diagnosed (de novo) and 12 who had previously undergone unsuccessful surgery (post-op, 11 macro and 1 micro) were studied. ATG 120 mg was initially given every 8 weeks for 24 weeks and subsequently changed according to GH levels: if ≤ ≤2.5 μg/l every 8 weeks (group A, 17 patients); if 2.5-5 μg/l every 6 weeks (group B, 15 patients); and if >5 μg/l every 4 weeks (group C, 19 patients). Treatment duration was 48-52 weeks. The primary objective was to control GH and IGF-I levels (GH≤2.5 μg/l and IGF-I normalized for age/gender). Secondary objectives were to assess GH, IGF-I, and acid-labile subunit (ALS) decrease, improvement of clinical symptoms and quality of life (QoL). Results: GH levels normalized in 32 patients (63%), similarly in de novo and post-op patients (72% vs 50%, p=0.48); in 100% of group A, in 73% of group B and in 21% of group C (p<0.0001). IGF-I levels normalized in 19 patients (37%), similarly in the de novo and post-op patients (33% vs 50%, p=0.48): in 65% of group A, 33% of group B, and in 16% of group C. Circulating GH levels decreased by 80±17%, IGF-I levels by 44±27%, and ALS by 30±17%. Symptoms (hyperhidrosis (68.6%), swelling (68.6%), asthenia (58.8%), spine arthralgia (54.9%), and paresthesias (52.9%) and QoL (from 9.1±7.9 to 6.1±6.6) significantly improved (p<0.001).
INTRODUCTION
First-line treatment of acromegaly with surgical adenomectomy in patients with macroadenomas fails in more than 50% of patients, as defined by increased levels of GH and IGF-I and persistence of clinical symptoms (1, 2) . The development of somatostatin analogues has made it possible to normalize GH and IGF-I levels and to improve clinical symptoms in most of the patients unsuccessfully operated (3). In recent years, independent studies have demonstrated beneficial effects of depot somatostatin analogues admin-istered to newly diagnosed patients with acromegaly as first-line treatment (4). Lanreotide is a synthetic octapeptide analogue of somatostatin, which binds preferentially to pituitary somatostatin receptors to inhibit GH secretion (5), therefore reducing IGF-I levels. Its efficacy in patients with active acromegaly was demonstrated in several clinical studies and a marketing authorization has been obtained in 52 countries world-wide for a micro-particle formulation. This first registered galenic form of lanreotide 30 mg enabled the release of the peptide over a period of 7 to 14 days after im administration. In order to further extend the duration of the release of the active ingredient, a new formulation of lanreotide, lanreotide Autogel (ATG) 60 mg, 90 mg and 120 mg was developed. The ATG formulation consists of a solution of lanreotide in water with no additional excipients. In a pharmacokinetic (PK) study conducted in 24 volunteers, ATG exhibited linear pharmacokinetics for the 60 to 120 mg doses and provided a prolonged dosing interval and good tolerability (6). Caron et al. (7) demon-strated that the micro-particle lanreotide and the ATG have equal efficacy, and proposed equivalent doses of the two formulations. Lucas et al. (8) have confirmed these results in a large multicenter trial. Efficacy of ATG was reported up to 3 yr from treatment (9). Other studies have subsequently demonstrated that ATG was as effective as octreotide-long acting release (LAR) in patients with acromegaly (10-12). Since data on the efficacy of ATG in patients with acromegaly are still limited (13), the current study was designed to assess efficacy and safety profile of ATG120 mg administered every 4 to 8 weeks for 12 months in somatostatin analogue-naive patients.
MATERIALS AND METHODS

Study design
This is an open, non-comparative, phase III, multicenter clinical study.
Objectives
The primary objective was to evaluate the efficacy of the ATG 120 mg on control of GH and IGF-I excess in acromegaly according to the currently accepted criteria (14). The secondary objectives were to assess decrease of GH, IGF-I, and acid-labile subunit (ALS) levels, improvement of clinical symptoms and QoL and safety profile.
Inclusion criteria
Patients aged ≥18 yr with active acromegaly [serum GH levels above 5 μg/l and/or above 1 μg/l after oral glucose tolerance test (OGTT) and abnormal IGF-I values], who signed the written informed consent form. Patients should not have undergone pituitary surgery less than 3 months before selection, somatostatin analogues (except for a pre-surgical treatment of less than 3 months) or radiotherapy.
Exclusion criteria
Patients who had undergone pituitary surgery less than 3 months before selection or previously treated with radiotherapy or previously treated with a somatostatin analogue for longer than 3 months or previously treated with a dopamine agonist (for a period >3 months and interrupted <6 months before selection) or requiring such treatment during the study. Patients suffering from active malignant disease, except basocellular carcinoma of the skin or in situ carcinoma of the uterine cervix. Women at risk of pregnancy during the study, not consenting to take adequate precautions against pregnancy. Pregnant or breast-feeding patients. Patients who had known hypersensitivity to any of the test materials or related compounds. Patients receiving any unlicensed drug within the previous 30 days or scheduled to receive any unlicensed drug other than ATG during the course of the study. Patients with evidence of drug/alcohol abuse. Patients unable or unwilling to fully comply with the protocol.
Determination of sample size
The determination of sample size was made using nQuery procedures and assuming a rate of patients with normalized GH levels at study end of at least 20% (minimum acceptable response rate) to 40% (minimum relevant clinical rate). With a type I error =0.05 (1-sided) and 90% power, the sample size required was of 54 patients.
Patients
Twenty-four centers participated in the study coordinated by G. Lombardi (University "Federico II", Naples, Italy). The inclusion of a minimum of 2 patients (at least 1 newly diagnosed) was required at each center. The study was approved by the Ethics Committees of all Centers. Patients gave their written informed consent prior to entering the study. The study was performed according to the principles defined by the declaration of Helsinki (1964) and subsequent modifications and in compliance with Good Clinical Practice (GCP). Of 64 patients screened, 1 was excluded since the adenoma spontaneously melted between selection and baseline visit. He never took the study drug and was excluded from the statistical analysis. Of the remaining 63 patients, 4 dropped out before week 16 and therefore were not assigned to any treatment subgroup and 8 patients dropped out between week 16 and the final visit; 1 of 8 withdrew his consent to take part in the study. Thus, the study population consists of 51 patients, 28 women and 23 men, aged 19-78 yr (median 50 yr). Fasting baseline GH levels (mean of 5 samples of a diurnal profile) were 19.4±21.3 μg/l (median 10.3 μg/l) and IGF-I levels were 703.4±274.2 μg/l (median 697 μg/l). IGF-I levels proved to be 2.5 times (median) above the upper limit of normal range (ULN) according to ageand sex-normative data. On magnetic resonance imaging (MRI), 30 patients had macroadenomas, 19 had microadenomas, and 2 had empty sella. Of the 51 patients, 39 were newly diagnosed (de novo) and 12 had previously undergone unsuccessful surgery (post-op, 11 macro and 1 micro). Table 1 shows the characteristics of the 2 groups at study entry.
Safety population
The safety population, as defined by the protocol, consists of patients who received at least 1 study drug dosing and includes 63 patients.
Hormonal evaluation
GH levels were assessed as a mean value of 5 samples at 30min intervals (starting between 08:00 and 09:00 h) taken at each visit before the injection of ATG. At inclusion (V0) and at final visit, GH concentrations after OGTT were also determined (data not shown). IGF-I and ALS levels were assessed as a single sample taken at each visit at the same time as the first GH sample. All hormonal parameters were assessed in a central laboratory (D.i.S.E.M. -University of Genoa).
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